Discover how to navigate inflation with long-term investments in resilient companies like Coca-Cola, AbbVie, and TC Energy. Read more about our stock picks on Seeking Alpha.

Leerink Partners analyst David Risinger has reiterated their bullish stance on ABBV stock, giving a Buy rating yesterday.Stay Ahead of the ...

AbbVie Inc (NYSE:ABBV)., a leading biopharmaceutical company, stands at a critical juncture as it navigates the loss of ...

Skyrizi had an estimated national TV ad spend of $367.7 million — the highest ad spend of any brand in the top 10.

On the third day, drugmakers provided updates on precision medicines for cancer and Alzheimer's, and Grail talked about the launch of a new version of the Galleri test.

AbbVie (ABBV) continues to dominate the adalimumab market with 72% share in the U.S., despite biosimilar threats gaining ground. Read more here.

AbbVie and Gilead are going back to their roots and leaning on their established areas of expertise to set themselves up for ...

AbbVie closed out the year on a high note, as its blockbuster biologic Skyrizi once again claimed the top spot in 2024’s ...

Signal Advisors Wealth LLC lifted its position in AbbVie Inc. (NYSE:ABBV – Free Report) by 16.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and ...

Shares of AbbVie Inc. ABBV slid 1.47% to $171.35 Wednesday, on what proved to be an all-around positive trading session for ...

Democratic-led states defend a Biden rule for DACA immigrants' healthcare, US regulators propose reducing nicotine in ...

The schizophrenia drug Emraclidine failed to perform in clinical trials but executives say it can still “play a role.” ...